NAC for early psychosis risk symptoms
Treatments studied
Part of Mental health clinical trials.
This trial studies whether NAC (a nutrient-like supplement) can reduce symptoms in people who are at high risk for developing psychosis. It may help by testing a safer, non-standard treatment approach for early warning signs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You meet “psychosis-risk syndrome” criteria based on a structured interview (SIPS)
- You can understand the study and sign informed consent
- If you can get pregnant, you’re using reliable birth control during the study (or you’ve been sterilized or are post-menopausal)
- You are NOT diagnosed with another mental health condition at the time of the study (with limited exceptions)
- You have not been on antipsychotic medicines at a therapeutic dose in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an NMDA-enhancer medicine to see if it can help people who are in the early “prodromal” stage—when symptoms are starting but full schizophrenia is not diagnosed yet. It aims to reduce or prevent worsening symptoms over the study period.
This study targets problems with “processing speed,” or how fast your brain handles information, to see if it can improve social functioning and lower the risk of developing full psychosis. It’s for people who are considered at high risk for psychosis but do not already have schizophrenia.
This study tests whether adding N-Acetylcysteine (a supplement) can help safely reduce antipsychotic medication in people with stable psychosis. If you are doing well on a steady dose of antipsychotics, you may be able to gradually lower your dose while taking this supplement.
This study looks at whether N-acetylcysteine (NAC), a supplement/medication, can help autism-related symptoms by trying to target brain chemistry. You may be able to join if you previously took part in a related NAC study and can keep your usual medications steady.
This trial tests whether a personalized care plan improves day-to-day functioning for people in the early stages of psychosis. It aims to see if adding structured support after a recent diagnosis can help you function better.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Hear when a new Prodromal Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.